WO2022145982A1 - 테트라덴테이트 질소 공여체 리간드를 포함하는 전이금속 착체 및 이를 포함하는 전기화학적 바이오센서 - Google Patents
테트라덴테이트 질소 공여체 리간드를 포함하는 전이금속 착체 및 이를 포함하는 전기화학적 바이오센서 Download PDFInfo
- Publication number
- WO2022145982A1 WO2022145982A1 PCT/KR2021/020070 KR2021020070W WO2022145982A1 WO 2022145982 A1 WO2022145982 A1 WO 2022145982A1 KR 2021020070 W KR2021020070 W KR 2021020070W WO 2022145982 A1 WO2022145982 A1 WO 2022145982A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- transition metal
- ligand
- metal complex
- complex
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 77
- 229910052723 transition metal Inorganic materials 0.000 title claims abstract description 49
- 150000003624 transition metals Chemical class 0.000 title claims abstract description 48
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title claims abstract description 22
- 229910052757 nitrogen Inorganic materials 0.000 title claims abstract description 17
- 150000002500 ions Chemical class 0.000 claims description 58
- -1 osmium halide Chemical class 0.000 claims description 39
- 108090000854 Oxidoreductases Proteins 0.000 claims description 29
- 102000004316 Oxidoreductases Human genes 0.000 claims description 29
- 102000004190 Enzymes Human genes 0.000 claims description 25
- 108090000790 Enzymes Proteins 0.000 claims description 25
- 229910052762 osmium Inorganic materials 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 22
- 229920000642 polymer Polymers 0.000 claims description 21
- 239000006163 transport media Substances 0.000 claims description 21
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 claims description 19
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 18
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical group CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 claims description 16
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical group OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims description 16
- 150000002391 heterocyclic compounds Chemical class 0.000 claims description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 claims description 9
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 claims description 9
- 239000011714 flavin adenine dinucleotide Substances 0.000 claims description 9
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 claims description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 125000005647 linker group Chemical group 0.000 claims description 7
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 6
- 230000002194 synthesizing effect Effects 0.000 claims description 6
- 101710088194 Dehydrogenase Proteins 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 150000003863 ammonium salts Chemical class 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- SMSLWFZHCONMGQ-UHFFFAOYSA-N 2-(1,3-thiazol-2-yl)-1,3-thiazole Chemical group C1=CSC(C=2SC=CN=2)=N1 SMSLWFZHCONMGQ-UHFFFAOYSA-N 0.000 claims description 4
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 4
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical group NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims description 4
- 108090000371 Esterases Proteins 0.000 claims description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000000033 alkoxyamino group Chemical group 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000005276 alkyl hydrazino group Chemical group 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims description 3
- 229910052741 iridium Inorganic materials 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 3
- 229910052703 rhodium Inorganic materials 0.000 claims description 3
- 229910052707 ruthenium Inorganic materials 0.000 claims description 3
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 2
- 108020005199 Dehydrogenases Proteins 0.000 claims description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- PFCMCBTZGOMQIN-UHFFFAOYSA-N indeno[1,2-d]pyridazin-1-one Chemical compound C1=CC=C2C3=CN=NC(=O)C3=CC2=C1 PFCMCBTZGOMQIN-UHFFFAOYSA-N 0.000 claims description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 description 126
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 87
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 82
- 238000006243 chemical reaction Methods 0.000 description 65
- 239000012153 distilled water Substances 0.000 description 58
- 239000000243 solution Substances 0.000 description 57
- 239000011521 glass Substances 0.000 description 56
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 54
- 239000000047 product Substances 0.000 description 52
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 47
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 36
- 239000007858 starting material Substances 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 239000008103 glucose Substances 0.000 description 30
- 239000008280 blood Substances 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 29
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 27
- 239000002904 solvent Substances 0.000 description 26
- 239000000203 mixture Substances 0.000 description 24
- 238000005481 NMR spectroscopy Methods 0.000 description 23
- 229940088598 enzyme Drugs 0.000 description 23
- 239000012265 solid product Substances 0.000 description 23
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 22
- 230000003647 oxidation Effects 0.000 description 22
- 238000007254 oxidation reaction Methods 0.000 description 22
- 239000002244 precipitate Substances 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 20
- 230000008859 change Effects 0.000 description 20
- 238000002484 cyclic voltammetry Methods 0.000 description 20
- 238000006722 reduction reaction Methods 0.000 description 20
- 239000003456 ion exchange resin Substances 0.000 description 19
- 229920003303 ion-exchange polymer Polymers 0.000 description 19
- 230000009467 reduction Effects 0.000 description 19
- 239000011347 resin Substances 0.000 description 19
- 229920005989 resin Polymers 0.000 description 19
- 229910052786 argon Inorganic materials 0.000 description 18
- 239000012300 argon atmosphere Substances 0.000 description 18
- 150000001768 cations Chemical class 0.000 description 18
- 239000000706 filtrate Substances 0.000 description 18
- 239000007789 gas Substances 0.000 description 18
- 239000011259 mixed solution Substances 0.000 description 18
- 239000012047 saturated solution Substances 0.000 description 18
- 238000005292 vacuum distillation Methods 0.000 description 18
- 238000002390 rotary evaporation Methods 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 16
- 238000003756 stirring Methods 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 239000003960 organic solvent Substances 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 239000002274 desiccant Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000010408 film Substances 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 108010015776 Glucose oxidase Proteins 0.000 description 9
- 150000002907 osmium Chemical class 0.000 description 9
- 230000027756 respiratory electron transport chain Effects 0.000 description 9
- 239000004366 Glucose oxidase Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 8
- 229910021607 Silver chloride Inorganic materials 0.000 description 8
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- SRBXXQDKBKTWOC-UHFFFAOYSA-J diazanium;hexachloroosmium(2-) Chemical compound [NH4+].[NH4+].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Os+4] SRBXXQDKBKTWOC-UHFFFAOYSA-J 0.000 description 8
- 229940116332 glucose oxidase Drugs 0.000 description 8
- 235000019420 glucose oxidase Nutrition 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 229910052709 silver Inorganic materials 0.000 description 8
- 239000004332 silver Substances 0.000 description 8
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 8
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 125000006575 electron-withdrawing group Chemical group 0.000 description 7
- 230000033116 oxidation-reduction process Effects 0.000 description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 7
- 229920003169 water-soluble polymer Polymers 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- YIVOAWVPVKOQSL-UHFFFAOYSA-N ethyl 2-(hydroxymethyl)pyridine-4-carboxylate Chemical compound CCOC(=O)C1=CC=NC(CO)=C1 YIVOAWVPVKOQSL-UHFFFAOYSA-N 0.000 description 5
- HLWYHRSTHMBVFV-UHFFFAOYSA-N ethyl 2-[(dipyridin-2-ylmethylamino)methyl]pyridine-4-carboxylate Chemical compound CCOC(C1=CC(CNC(C2=NC=CC=C2)C2=NC=CC=C2)=NC=C1)=O HLWYHRSTHMBVFV-UHFFFAOYSA-N 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- GBMRUSRMPOUVEK-UHFFFAOYSA-N (4-methoxypyridin-2-yl)methanol Chemical compound COC1=CC=NC(CO)=C1 GBMRUSRMPOUVEK-UHFFFAOYSA-N 0.000 description 4
- PBDFBZPTRXMFBL-UHFFFAOYSA-N 2-(chloromethyl)-4-methoxypyridine;hydrochloride Chemical compound Cl.COC1=CC=NC(CCl)=C1 PBDFBZPTRXMFBL-UHFFFAOYSA-N 0.000 description 4
- QYZAHCKDLDXPKU-UHFFFAOYSA-N 2-(hydroxymethyl)pyridine-4-carboxamide Chemical compound NC(=O)C1=CC=NC(CO)=C1 QYZAHCKDLDXPKU-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 4
- 229940081066 picolinic acid Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000013076 target substance Substances 0.000 description 4
- DENUXIGZQGZLCB-UHFFFAOYSA-N 2-(chloromethyl)pyridine-4-carbonitrile Chemical compound ClCC1=CC(C#N)=CC=N1 DENUXIGZQGZLCB-UHFFFAOYSA-N 0.000 description 3
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 3
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 3
- VFBHFOVPCPTMMZ-UHFFFAOYSA-N 4-(2-aminoethyl)-2-[(dipyridin-2-ylmethylamino)methyl]-1H-pyridine-2-carboxamide Chemical compound NCCC1=CC(CNC(C2=NC=CC=C2)C2=NC=CC=C2)(C(N)=O)NC=C1 VFBHFOVPCPTMMZ-UHFFFAOYSA-N 0.000 description 3
- RPHHYRNGCJYQSP-UHFFFAOYSA-N 4-bromopyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC(Br)=CC=N1 RPHHYRNGCJYQSP-UHFFFAOYSA-N 0.000 description 3
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 3
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
- 108010025188 Alcohol oxidase Proteins 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- 108010015428 Bilirubin oxidase Proteins 0.000 description 3
- 108010089254 Cholesterol oxidase Proteins 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- MLCPWIJYAMXLDB-UHFFFAOYSA-N [2-[(dipyridin-2-ylmethylamino)methyl]pyridin-4-yl]methanol Chemical compound OCC1=CC(CNC(C2=NC=CC=C2)C2=NC=CC=C2)=NC=C1 MLCPWIJYAMXLDB-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- MUUDQLHCIAOWPR-UHFFFAOYSA-N diethyl pyridine-2,4-dicarboxylate Chemical compound CCOC(=O)C1=CC=NC(C(=O)OCC)=C1 MUUDQLHCIAOWPR-UHFFFAOYSA-N 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000006479 redox reaction Methods 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000013077 target material Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- LWGRHHZXVIERGZ-UHFFFAOYSA-N (4-methoxypyridin-2-yl)carbamic acid Chemical compound COC1=CC(=NC=C1)NC(=O)O LWGRHHZXVIERGZ-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- VGUWFGWZSVLROP-UHFFFAOYSA-N 1-pyridin-2-yl-n,n-bis(pyridin-2-ylmethyl)methanamine Chemical compound C=1C=CC=NC=1CN(CC=1N=CC=CC=1)CC1=CC=CC=N1 VGUWFGWZSVLROP-UHFFFAOYSA-N 0.000 description 2
- KXZQYLBVMZGIKC-UHFFFAOYSA-N 1-pyridin-2-yl-n-(pyridin-2-ylmethyl)methanamine Chemical compound C=1C=CC=NC=1CNCC1=CC=CC=N1 KXZQYLBVMZGIKC-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- STMDPCBYJCIZOD-UHFFFAOYSA-N 2-(2,4-dinitroanilino)-4-methylpentanoic acid Chemical compound CC(C)CC(C(O)=O)NC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O STMDPCBYJCIZOD-UHFFFAOYSA-N 0.000 description 2
- LJCNDNBULVLKSG-UHFFFAOYSA-N 2-aminoacetic acid;butane Chemical compound CCCC.CCCC.NCC(O)=O LJCNDNBULVLKSG-UHFFFAOYSA-N 0.000 description 2
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 2
- CMMURVLHXMNTHY-UHFFFAOYSA-N 4-methylpyridine-2-carboxylic acid Chemical compound CC1=CC=NC(C(O)=O)=C1 CMMURVLHXMNTHY-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 229920002491 Diethylaminoethyl-dextran Polymers 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 108010073450 Lactate 2-monooxygenase Proteins 0.000 description 2
- 239000004642 Polyimide Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108010055297 Sterol Esterase Proteins 0.000 description 2
- 102000000019 Sterol Esterase Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000002041 carbon nanotube Substances 0.000 description 2
- 229910021393 carbon nanotube Inorganic materials 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002848 electrochemical method Methods 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002908 osmium compounds Chemical class 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- 239000004945 silicone rubber Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- YFSUTJLHUFNCNZ-UHFFFAOYSA-M 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F YFSUTJLHUFNCNZ-UHFFFAOYSA-M 0.000 description 1
- JPMRGPPMXHGKRO-UHFFFAOYSA-N 2-(chloromethyl)pyridine hydrochloride Chemical compound Cl.ClCC1=CC=CC=N1 JPMRGPPMXHGKRO-UHFFFAOYSA-N 0.000 description 1
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- DYHMIVKBJSIOCH-UHFFFAOYSA-N 4-methoxypyridine-2-carboxamide Chemical compound COC1=CC=NC(C(N)=O)=C1 DYHMIVKBJSIOCH-UHFFFAOYSA-N 0.000 description 1
- UELRAKDBDJRXST-UHFFFAOYSA-M 4-methoxypyridine-2-carboxylate Chemical compound COC1=CC=NC(C([O-])=O)=C1 UELRAKDBDJRXST-UHFFFAOYSA-M 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108700023156 Glutamate dehydrogenases Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical class CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 101710138959 NAD-specific glutamate dehydrogenase Proteins 0.000 description 1
- 229920000557 Nafion® Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- BKRKYEFQSANYGA-UHFFFAOYSA-N bromo-methyl-triphenyl-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(Br)(C=1C=CC=CC=1)(C)C1=CC=CC=C1 BKRKYEFQSANYGA-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical class [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 235000012209 glucono delta-lactone Nutrition 0.000 description 1
- 229960003681 gluconolactone Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- ARRNBPCNZJXHRJ-UHFFFAOYSA-M hydron;tetrabutylazanium;phosphate Chemical compound OP(O)([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC ARRNBPCNZJXHRJ-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- MJIVRKPEXXHNJT-UHFFFAOYSA-N lutidinic acid Chemical compound OC(=O)C1=CC=NC(C(O)=O)=C1 MJIVRKPEXXHNJT-UHFFFAOYSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002907 paramagnetic material Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920002717 polyvinylpyridine Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- SHNUBALDGXWUJI-UHFFFAOYSA-N pyridin-2-ylmethanol Chemical compound OCC1=CC=CC=N1 SHNUBALDGXWUJI-UHFFFAOYSA-N 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- FHCPAXDKURNIOZ-UHFFFAOYSA-N tetrathiafulvalene Chemical compound S1C=CSC1=C1SC=CS1 FHCPAXDKURNIOZ-UHFFFAOYSA-N 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/002—Osmium compounds
- C07F15/0026—Osmium compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
- A61B5/14865—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/002—Electrode membranes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/004—Enzyme electrodes mediator-assisted
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3275—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction
- G01N27/3277—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction being a redox reaction, e.g. detection by cyclic voltammetry
Definitions
- the present invention relates to a transition metal complex comprising a tetradentate nitrogen donor ligand useful as an electron transport medium, and an electrochemical biosensor comprising the same.
- Diabetes mellitus is a disease that occurs when high blood sugar levels are maintained for a long time and causes complications such as cardiovascular disease, stroke, and kidney disease.
- cardiovascular disease cardiovascular disease, stroke, and kidney disease.
- hypoglycemia may occur, which may lead to shock or death.
- the CGMS sensor is a device that is inserted into the subcutaneous tissue and continuously measures the glucose concentration through intercellular fluid, not blood.
- the CGMS has the advantage of checking the change and tendency of the blood sugar level in a day. This allows the patient to quickly recognize hyperglycemia or hypoglycemia, and the ability to manage blood sugar can be further improved.
- a biosensor refers to a device that selectively detects a biological sample and converts it into a specific signal.
- an enzyme-based biosensor using an electrochemical method is preferred because of its improved selectivity by enzymes, as well as possible miniaturization and measurement accuracy.
- Blood glucose biosensors using electrochemical methods are largely divided into first-generation and second-generation methods.
- the first-generation blood glucose sensor was first developed by Clark and Lyon, and is a method of measuring blood glucose levels through the oxygen concentration reduced through an enzyme oxidation-reduction reaction and the change in the concentration of hydrogen peroxide generated.
- the blood glucose sensor transfers electrons generated through the oxidation-reduction reaction of enzymes to the electrode through an electron transfer medium.
- the second-generation sensor has many advantages compared to the first-generation sensor in that there is less error depending on the oxygen concentration and the electron transfer reaction by the medium is efficient and fast. For this reason, a second-generation sensor method including an electron transfer medium is being applied to the CGMS blood glucose sensor.
- An electrochemical enzyme-based blood glucose biosensor is generally composed of an enzyme, an electron transfer medium, and an electrode. At first, glucose is oxidized to gluconolactone by an enzyme, and then the reduced enzyme is oxidized and donates electrons to an electron transport medium. Then, as the reduced medium is oxidized, electrons are transferred to the electrode. From this series of processes, the blood sugar level can be confirmed as an electrical signal.
- Enzymes applied to the blood glucose sensor generally include glucose oxidase (GOx) and glucose dehydrogenase (GDH).
- GOx selectively oxidizes glucose and has been widely applied in blood glucose sensors because of its low cost and high stability.
- GDH glucose dehydrogenase
- GOx selectively oxidizes glucose and has been widely applied in blood glucose sensors because of its low cost and high stability.
- GOx is greatly affected by oxygen in the oxidation process, it is known that the GOx-based blood glucose sensor has an error in measuring the blood glucose level higher than the actual level at a high altitude or low atmospheric pressure.
- GDH is characterized in that it can selectively oxidize glucose independent of oxygen concentration.
- FAD flavin adenine dinucleotide
- Electrochemical properties of electron transport mediators are key factors that can affect rapid electron transport, selectivity, and sensitivity in blood glucose sensors. Interference of interfering substances in the living body can be avoided according to the potential of the mediator, and redox shuttling, a phenomenon in which the mediator generates an error current through repeated oxidation/reduction reactions between adjacent electrodes, can be thermodynamically avoided. . Therefore, in order for the electron transport medium to perform an efficient function, it is ideal to have an appropriately low oxidation-reduction potential (-0.2V ⁇ 0V vs Ag/AgCl). In addition, both the oxidizing and reducing species must be chemically stable and non-toxic in the body.
- Electron transport mediators that have been studied a lot so far include ferrocene derivatives, ferricyanide, tetrathiafulvalene, and dislocation metal complexes. Although they have been studied extensively as electron transport media, there is still a need for a new electron transport media that has high efficiency, is stable, and has no toxicity in the body.
- the present inventors repeated studies on a transition metal complex useful as an electron transport medium for an electrochemical biosensor, and as a result, as a tetradentate ligand (tetradentate ligand), tris-2-pyridylmethylamine (tris( In the case of introducing 2-pyridylmethyl)amine (TPMA), it exhibits exceptionally high stability compared to conventional monodentate or bidentate ligands, and transition metal complexes prepared from these can be easily synthesized and exhibit stable electrochemical characteristics Confirmed and completed the present invention.
- tetradentate ligand tris-2-pyridylmethylamine
- Another object of the present invention is to provide an electrochemical biosensor comprising a redox polymer including the transition metal complex.
- Another object of the present invention is to provide a method for preparing the transition metal complex.
- a transition metal complex including a tetradentate nitrogen donor ligand useful as an electron transport medium may be provided.
- a method for preparing the transition metal complex may be provided.
- a device comprising the transition metal complex as an electron transport medium may be provided.
- an enzyme capable of redoxing a liquid biological sample capable of redoxing a liquid biological sample; And a sensing film for an electrochemical biosensor comprising the transition metal complex as an electron transport medium may be provided.
- the transition metal complex comprising a tetradentate nitrogen donor ligand according to the present invention improves the performance of an electrochemical sensor excellently when used in an electrochemical sensor.
- 1 is a view showing various synthetic methods for preparing tetradentate ligands for preparing the transition metal complex of the present invention.
- FIG 3 is a diagram showing the crystal structure of [Os(TPMA)Cl 2 ] + (PF 6 - ).
- FIG. 5 is a diagram showing the change in the mass signal confirmed on ESI-MS of the hydroxymethyl TPMA osmium complex.
- FIGS. 7a to 7c are diagrams showing structures and oxidation/reduction potentials of TPMA-based osmium complexes.
- 8A and 8B are graphs comparing the potential values of the [Os(TPMA)Cl 2 ] + (PF 6 - ) complexes through the cyclic voltammetry according to the substituents.
- 8A is a graph comparing complexes having EDG (18, 21, 23)
- FIG. 8B is a graph comparing complexes having EWG (18, 19, 20, 22).
- the current value was corrected to 18, and was measured by injection at 10 mV/s in 0.1 M TPMP in CH 3 CN solution.
- 16 is a graph showing the CV data of [Os(TPMA)(L) 1-2 ] n+ (PF 6 - ) n Complex (26).
- 17 is a graph showing the CV data of [Os(TPMA)(L) 1-2 ] n+ (PF 6 - ) n Complex (27).
- 21 is a graph showing the CV data of [Os(TPMA)(L) 1-2 ] n+ (PF 6 - ) n Complex (31).
- 25 is a graph showing the CV data of [Os(TPMA)(L) 1-2 ] n+ (PF 6 - ) n Complex (35).
- the present invention provides a transition metal complex comprising a tetradentate nitrogen donor ligand useful as an electron transport medium.
- the transition metal complex may be represented by Formula 1 or 2 below.
- M may be one selected from the group consisting of Fe, Co, Ru, Os, Rh and Ir;
- C a , C b and C c are each independently a heterocyclic compound containing at least one nitrogen atom, preferably connected to an amine group and a methylene group at the 2-position of the ring compound;
- L m1 and L m2 are each independently a coordinated monodentate ligand
- L b is a bidentate ligand comprising nitrogen or oxygen
- m is a negative or positive charge representing -1 to -5 or 1 to 5;
- R 1 , R 2 and R 3 are each independently a linker introduced with a reactive group capable of connecting to a polymer, an electron donating group (EDG) or an electron accepting group (EWG) for controlling the oxidation/reduction potential is a functional group;
- EDG electron donating group
- EWG electron accepting group
- X is a counter ion, preferably a counter ion selected from the group consisting of F, Cl, Br, I and PF 6 ;
- n means the number of counterions, and is 1 to 5.
- the transition metal complex may include a tetradentate ligand represented by Formula 3 below.
- C a , C b and C c are each independently a heterocyclic compound containing at least one nitrogen atom;
- R 1 , R 2 and R 3 are each independently a linker introduced with a reactive group capable of connecting to a polymer, an electron donating group (EDG) or an electron accepting group (EWG) for controlling the oxidation/reduction potential is a functional group.
- EDG electron donating group
- EWG electron accepting group
- the tetradentate ligand of Formula 3 may be one of the ligands having the following structure:
- the heterocyclic compound may be connected to an amine group and a methylene group at the 2-position, and three nitrogens of the three hetero rings and one nitrogen at the center connecting the three hetero rings to each other are transition metal M can be connected with
- R 1 , R 2 , and R 3 are each independently —H; -F; -Cl; -Br; -I; -NO 2 ; -CN; -CO 2 H; -SO 3 H; -NHNH 2 ; -SH; -OH; -NH 2 ; -CH 2 OH; -CONHCH 2 CH 2 NH 2 ; or substituted or unsubstituted alkoxycarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkoxy, alkylamino, dialkylamino, alkanylamino, arylcarboxyamido, hydrazino, alkylhydrazino, hydrazino hydroxyamino, alkoxyamino, alkylthio, alkenyl, aryl or alkyl.
- L m1 and L m2 are monodentate ligands, and each independently -H, -F, -Cl, -Br, -I, -NO 2 , -NCCH 3 , -CO, -OH 2 , - It may be a heterocyclic compound including one or more NH 3 or nitrogen atoms.
- L b - L b is It is a bidentate ligand and may be catechol, acetylacetone, 2-picolinic acid, 2-pyridinecarboxamide, 2,2'-bipyridine or 2,2'-bithiazole.
- the heterocyclic compound is imidazole, pyridine, pyrimidine, pyrazole, isoxazole, oxazole, thiazole, benzothiazole, benzimidazole, benzoxazole and diazafluorenone group consisting of It may be at least one selected from
- amino, alkoxyamino, alkylthio, alkenyl, aryl, alkyl and tricyclic heterocycles are substituted, these are -F, -Cl, -Br, -I, -OH, oxo, an alkyl group having 1 to 3 carbon atoms and an alkyl group having 1 to 3 carbon atoms.
- One or more selected from the group consisting of 1 to 3 alkoxy groups may be substituted, preferably 1 to 3.
- the transition metal complex of Formula 1 or 2 according to the present invention may be one of the transition metal complexes shown in Table 1 below:
- the present invention provides a method for preparing a transition metal complex useful as the electron transport medium.
- the transition metal complex useful as the electron transport medium according to the present invention is a transition metal salt, preferably via an osmium salt. can be manufactured.
- the salt of the transition metal may be an ammonium salt of a halogenated transition metal of Formula 4 below,
- M may be one selected from the group consisting of Fe, Co, Ru, Os, Rh and Ir;
- X is F, Cl, Br, or I.
- the ammonium salt of the halogenated transition metal of Formula 4 may be ammonium hexachloroosmate of Formula 5, which is commercially available.
- the method for preparing a transition metal complex according to the present invention may be synthesized using a tris-pyridinemethylamine-based ligand and an ammonium salt of a transition metal halide.
- a tris-pyridinemethylamine-based ligand and an ammonium salt of a transition metal halide.
- the following steps may be included:
- the transition metal complex may include a tetradentate ligand represented by Formula 3 below.
- C a , C b and C c are each independently a heterocyclic compound containing at least one nitrogen atom;
- R 1 , R 2 and R 3 are each independently a linker into which a reactive group capable of being linked to a polymer is introduced.
- the first step is a step of introducing tris-pyridinemethylamine-based ligand of Formula 3 into an osmium salt of Formula 5 in a tetravalent ionic state, and synthesizing it in the form of an osmium complex represented by Formula 6 in a trivalent ionic state.
- one or two types of monodentate or bidentate trigand selected from the group consisting of N-N ligand, N-ligand, N-O ligand and O-O ligand are introduced into the osmium complex synthesized in the first step by formula 7 to 11 is a step of synthesizing the osmium complex represented by any one of.
- one N-N ligand, two N ligands, one N ligand, one N-O ligand, and one O-O ligand may be introduced into the synthesized osmium complex of formula (6).
- the N ligand may be -NO 2 , -NCCH 3 , -NH 3 or a heterocyclic compound including one or more nitrogen atoms.
- the N-N ligand may be 2-pyridinecarboxamide, 2,2'-bipyridine, 2,2'-bithiazole, or 2-pyridylmethylamine.
- the N-O ligand may be 2-picolinic acid, 2-aminophenol or 2-hydroxymethylpyridine.
- the O-O ligand may be catechol or acetylacetone.
- the electron transfer mediator transition metal complex according to the present invention serves to transfer electrons obtained by reduction (glucose oxidation) of an oxidoreductase, polyvinylpyridine (Poly (vinylpyridine): PVP) or polyvinylimidazole ( Poly(vinylimidazole): PVI), poly allyl glycidyl ether (Poly allyl glycidyl ether: PAGE), an oxidation-reduction polymer connected to a polymer matrix corresponding to a polymer backbone such as at least one selected from the group consisting of form can be used.
- a further aspect of the present invention relates to a redox polymer comprising the transition metal complex for the electron transport mediator and a polymer backbone.
- the oxidation-reduction polymer may include a linker structure connecting the polymer backbone and an organic-based electron transport mediator.
- a further aspect of the present invention relates to a sensing membrane for an electrochemical biosensor comprising an enzyme capable of redoxing a liquid biological sample and an electron transfer mediator including the transition metal complex.
- the oxidoreductase is a generic term for enzymes that catalyze the redox reaction of a living body.
- a target material to be measured for example, a biosensor, refers to an enzyme that is reduced by reacting with the target material to be measured.
- the reduced enzyme reacts with the electron transfer mediator, and the target substance is quantified by measuring a signal such as a change in current generated at this time.
- the oxidoreductase usable in the present invention may be at least one selected from the group consisting of various dehydrogenases, oxidases, esterases, etc., depending on the redox or detection target substance, From among the enzymes belonging to the enzyme group, an enzyme having the target material as a substrate may be selected and used.
- the oxidoreductase is glucose dehydrogenase, glutamate dehydrogenase, glucose oxidase, cholesterol oxidase, cholesterol esterase, rock.
- At least one selected from the group consisting of lactate oxidase, ascorbic acid oxidase, alcohol oxidase, alcohol dehydrogenase, bilirubin oxidase, etc. can be selected from the group consisting of lactate oxidase, ascorbic acid oxidase, alcohol oxidase, alcohol dehydrogenase, bilirubin oxidase, etc.
- the oxidoreductase may include a cofactor that serves to store the hydrogen taken by the oxidoreductase from the target substance to be measured (eg, the target substance), for example, flavin adenine dinu. It may be one or more selected from the group consisting of cleotatide (flavin adenine dinucleotide, FAD), nicotinamide adenine dinucleotide (NAD), and pyrroloquinoline quinone (PQQ).
- FAD fluvin adenine dinucleotide
- NAD nicotinamide adenine dinucleotide
- PQQ pyrroloquinoline quinone
- glucose dehydrogenase when measuring blood glucose concentration, glucose dehydrogenase (GDH) can be used as the oxidoreductase, and the glucose dehydrogenase is a flavin adenine dinucleotide containing FAD as a cofactor-glucose dehydrogenase. It may be an enzyme (flavin adenine dinucleotide-glucose dehydrogenase, FAD-GDH), and/or nicotinamide adenine dinucleotide-glucose dehydrogenase containing FAD-GDH as a cofactor.
- the usable oxidoreductase is FAD-GDH (eg, EC 1.1.99.10, etc.), NAD-GDH (eg, EC 1.1.1.47, etc.), PQQ-GDH (eg, EC1.1.5.2, etc.) , glutamic acid dehydrogenase (eg, EC 1.4.1.2, etc.), glucose oxidase (eg, EC 1.1.3.4, etc.), cholesterol oxidase (eg, EC 1.1.3.6, etc.), cholesterol esterase (eg, EC 3.1.
- FAD-GDH eg, EC 1.1.99.10, etc.
- NAD-GDH eg, EC 1.1.1.47, etc.
- PQQ-GDH eg, EC1.1.5.2, etc.
- glutamic acid dehydrogenase eg, EC 1.4.1.2, etc.
- glucose oxidase eg, EC 1.1.3.4, etc
- lactate oxidase eg, EC 1.1.3.2, etc.
- ascorbic acid oxidase eg, EC 1.10.3.3, etc.
- alcohol oxidase eg, EC 1.1.3.13, etc.
- alcohol dehydrogenase eg , EC 1.1.1.1, etc.
- bilirubin oxidase eg, EC 1.3.3.5, etc.
- the oxidoreductase is a glucose dehydrogenase capable of maintaining an activity of 70% or more in a buffer solution at 37° C. for one week.
- the sensing membrane according to the present invention may contain 20 to 700 parts by weight of the redox polymer, such as 60 to 700 parts by weight or 30 to 340 parts by weight, based on 100 parts by weight of the oxidoreductase.
- the content of the oxidation-reduction polymer may be appropriately adjusted according to the activity of the oxidoreductase.
- the sensing film according to the present invention may further include carbon nanotubes to increase film performance. Specifically, when carbon nanotubes are used together with a transition metal complex, in particular, osmium, the electron transfer rate is increased, so that the performance of the sensing film can be further improved.
- a transition metal complex in particular, osmium
- the sensing film according to the present invention may further include a crosslinking agent.
- the sensing membrane according to the present invention contains one or more additives selected from the group consisting of surfactants, water-soluble polymers, quaternary ammonium salts, fatty acids, thickeners, etc. as a dispersant for dissolving reagents, pressure-sensitive adhesives for preparing reagents, stabilizers for long-term storage, etc. may be additionally included for the role of
- the surfactant may serve to distribute the composition evenly over the electrode when dispensing the composition to be dispensed with a uniform thickness. 1 selected from the group consisting of Triton X-100, sodium dodecyl sulfate, perfluorooctane sulfonate, sodium stearate, etc. as the surfactant More than one species can be used.
- the surfactant is added to 100 parts by weight of the oxidoreductase in order to properly perform the role of dispensing the reagent evenly on the electrode and dispensing the reagent with a uniform thickness when dispensing the reagent. to 25 parts by weight, such as 10 to 25 parts by weight.
- a surfactant when using an oxidoreductase having an activity of 700 U/mg, 10 to 25 parts by weight of a surfactant may be contained based on 100 parts by weight of the oxidoreductase, and when the activity of the oxidoreductase is higher than this, the content of the surfactant can be adjusted lower than this.
- the water-soluble polymer may serve to assist in stabilizing and dispersing the enzyme as a polymer support of the reagent composition.
- the water-soluble polymer polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), polyfluorosulfonate (polyperfluoro sulfonate), hydroxyethyl cellulose (HEC), hydroxy At least one selected from the group consisting of propyl cellulose (hydroxypropyl cellulose; HPC), carboxy methyl cellulose (CMC), cellulose acetate, polyamide, and the like may be used.
- the reagent composition according to the present invention contains 10 to 70 parts by weight of the water-soluble polymer based on 100 parts by weight of the oxidoreductase, such It may be contained in an amount of 30 to 70 parts by weight.
- an oxidoreductase having an activity of 700 U/mg it may contain 30 to 70 parts by weight of a water-soluble polymer based on 100 parts by weight of the oxidoreductase, and when the activity of the oxidoreductase is higher than this, the content of the water-soluble polymer can be adjusted lower than this.
- the water-soluble polymer may have a weight average molecular weight of about 2,500 g/mol to 3,000,000 g/mol, for example, about 5,000 g/mol to 1,000,000 g/mol, in order to effectively perform a kinetics helping the stabilization and dispersing of the support and the enzyme. have.
- the thickener serves to firmly attach the reagent to the electrode.
- the thickener at least one selected from the group consisting of natrozole, diethylaminoethyl-dextran hydrochloride (DEAE-Dextran hydrochloride), and the like may be used.
- an oxidoreductase having an activity of 700 U/mg it may contain 30 to 90 parts by weight of a thickener based on 100 parts by weight of the oxidoreductase, and when the activity of the oxidoreductase is higher than this, the content of the thickener can be adjusted lower than this.
- the present invention may be a device including such an organic electron transport medium, preferably an implantable device, more specifically, a device insertable into the human body.
- the device may be an electrochemical biosensor, and more preferably an electrochemical glucose (blood sugar) sensor.
- the type of the electrochemical biosensor is not limited, but may preferably be a continuous blood glucose monitoring sensor.
- the present invention provides, for example, an electrode, an insulator, a substrate, a sensing layer including the redox polymer and a redox enzyme, and a diffusion layer ), a protection layer, and the like.
- the electrode two types of electrodes such as a working electrode and a counter electrode may be included, and three types of electrodes such as a working electrode, a counter electrode and a reference electrode may be included.
- the biosensor according to the present invention includes an oxidation-reduction polymer comprising the organic-based electron transfer mediator of Formula 1 and a liquid biological sample on a substrate having at least two, preferably two or three electrodes.
- It may be an electrochemical biosensor manufactured by applying a reagent composition containing an enzyme capable of oxidation-reduction and then drying.
- a working electrode and a counter electrode are provided on opposite sides of a substrate, and a sensing film containing an oxidation-reduction polymer having an organic-based electron transport medium according to the present invention is laminated on the working electrode.
- a planar electrochemical biosensor characterized in that an insulator, a diffusion film and a protective film are sequentially stacked on both sides of a substrate provided with a working electrode and a counter electrode.
- the substrate may be made of one or more materials selected from the group consisting of polyethylene terephthalate (PET), polycarbonate (PC), and polyimide (PI).
- PET polyethylene terephthalate
- PC polycarbonate
- PI polyimide
- the working electrode may use a carbon, gold, platinum, silver or silver/silver chloride electrode.
- a gold, platinum, silver, or silver/silver chloride electrode can be used as the counter electrode, and a three-electrode including a reference electrode can be used.
- a gold, platinum, silver, or silver/silver chloride electrode may be used as a reference electrode, and a carbon electrode may be used as a counter electrode.
- Nafion, cellulose acetate, silicone rubber may be used as the diffusion film, and silicone rubber, polyurethane, polyurethane-based copolymer, etc. may be used as the protective film, but is not limited thereto.
- silver chloride or silver may be used because the counter electrode also serves as a reference electrode, and in the case of three electrodes, silver chloride or silver is used as the reference electrode, and a carbon electrode may be used as the counter electrode.
- the embodiment of the present invention exemplifies a biosensor for measuring glucose as an applicable example of the electrochemical biosensor, cholesterol, lactate, creatinine, hydrogen peroxide, cholesterol, lactate, creatinine, hydrogen peroxide, It can be applied to biosensors for quantification of various substances such as alcohol, amino acids, and glutamate.
- TPMA ligands having various functional groups were synthesized according to the synthetic route shown in FIG . 1 .
- Bis-2-pyridylmethylamine ( 1 ) and tris-2-pyridylmethylamine ( 10 ) were synthesized through reductive amination between 2-pyridylaldehyde and 2-pyridylmethylamine.
- Other ligands ( 11, 12, 15, 16 ) were synthesized by slightly modifying methods known in the literature (Kojima, T.; Fukuzumi, S. Chem. Eur. J. 2007 , 13, 8212 - 8222).
- the water layer is extracted 3 times with CH 2 Cl 2 . Thereafter, anhydrous MgSO 4 was added to the collected organic layer to remove water, and a desiccant was filtered using a glass filter under reduced pressure. The organic solvent is removed using a rotary evaporation dryer.
- Anhydrous MgSO 4 was added to the collected organic layers to remove water, and a desiccant was filtered using a glass filter under reduced pressure.
- the organic solvent is removed using a rotary evaporation dryer. When it is confirmed that the reaction has completely progressed, the solvent is removed using a rotary evaporation dryer.
- the water layer is extracted 3 times with CH 2 Cl 2 . Thereafter, anhydrous MgSO 4 was added to the collected organic layer to remove water, and a desiccant was filtered using a glass filter under reduced pressure. The organic solvent is removed using a rotary evaporation dryer.
- the starting material (12) (1.35 g, 3.7 mmol) was dissolved in a minimum amount of CH 2 Cl 2 and slowly added to purified ethylenediamine (22.5 g, 370 mmol).
- a reflux belt is installed in the reaction flask and stirred at 80 o C for 16 hours. After the reaction is complete, cool to room temperature and pour 30 mL of water. After transferring the product in the flask to a separatory funnel, the water layer is extracted 3 times with CH 2 Cl 2 . Thereafter, anhydrous MgSO 4 was added to the collected organic layer to remove water, and a desiccant was filtered using a glass filter under reduced pressure. The organic solvent is removed using a rotary evaporation dryer.
- Monodentate ligands such as 1-methylimidazole and pyridine and bidentate ligands such as 4-methoxy-2-pyridylcarbocyamide, picolinic acid, catechol, and acetylacetone [Os(TPMA)Cl 2 ] [Os(TPMA)(L) 1-2 ] + (PF 6 - )-based complexes could be synthesized through an exchange reaction with a chlorine (Cl) ligand by reacting with + (PF 6 - ). This synthetic reaction scheme is shown in FIG. 4 .
- TPMA-based osmium complexes were initially obtained in the form of PF 6 - counterions, and [Os(TPMA)Cl 2 ] + (Cl - ) or [Os(TPMA)(L) using Cl - ion exchange resin. ) 1-2 ] n+ (Cl - ) n type complex was obtained.
- Most of the TPMA-based osmium complexes showed a large difference in solubility depending on the form of the counterion.
- PF 6 - is in the form of a counterion, it shows good solubility in acetonitrile and acetone solvents, but shows poor solubility in water and methanol.
- Cl - counterion it showed good solubility in water and methanol, and hardly dissolved in organic solvents such as acetonitrile and acetone.
- Ammonium hexachloroosmate (30 mg, 0.068 mmol) and starting material (10) (20 mg, 0.068 mmol) are put in a glass culture tube, and ethylene glycol (2 mL) is added to make a mixed solution. After that, argon gas was blown in for 10 minutes to create an argon atmosphere in the glass culture tube, and then refluxed at 140 o C for 6 hours. Add an excess of ammonium hexafluorophosphate to distilled water and slowly drop the reaction solution into a saturated solution. A precipitate formed in the solution was filtered and washed with distilled water and an excess of diethyl ether to obtain a green solid product 18 having a counter ion of PF 6 ⁇ .
- Ammonium hexachloroosmate (129 mg, 0.293 mmol) and starting material (11) (120 mg, 0.293 mmol) are put in a glass culture tube, and ethylene glycol (3 mL) is added to make a mixed solution. After that, argon gas was blown in for 10 minutes to create an argon atmosphere in the glass culture tube, and then refluxed at 140 o C for 6 hours. Add an excess of ammonium hexafluorophosphate to distilled water and slowly drop the reaction solution into a saturated solution. A precipitate formed in the solution was filtered and washed with distilled water and an excess of diethyl ether to obtain a brown solid product 19 having a counter ion of PF 6 - .
- Ammonium hexachloroosmate (327 mg, 0.744 mmol) and starting material (12) (270 mg, 0.744 mmol) are put in a glass culture tube, and ethylene glycol (3 mL) is added to make a mixed solution. After that, argon gas was blown in for 10 minutes to create an argon atmosphere in the glass culture tube, and then refluxed at 140 o C for 6 hours. Add an excess of ammonium hexafluorophosphate to distilled water and slowly drop the reaction solution into a saturated solution. A precipitate formed in the solution was filtered and washed with distilled water and an excess of diethyl ether to obtain a brown solid product 20 having a counter ion of PF 6 - .
- Ammonium hexachloroosmate (62 mg, 0.141 mmol) and starting material (13) (45 mg, 0.141 mmol) are put in a glass culture tube, and ethylene glycol (3 mL) is added to make a mixed solution. After that, argon gas was blown in for 10 minutes to create an argon atmosphere in the glass culture tube, and then refluxed at 140 o C for 6 hours. Add an excess of ammonium hexafluorophosphate to distilled water and slowly drop the reaction solution into a saturated solution.
- Ammonium hexachloroosmate (326 mg, 0.742 mmol) and starting material (14) (280 mg, 0.742 mmol) are put in a glass culture tube, and ethylene glycol (3 mL) is added to make a mixed solution. After that, argon gas was blown for 10 minutes to make the inside of the glass culture tube an argon atmosphere, and then refluxed at 140 o C for 16 hours. Add an excess of ammonium hexafluorophosphate to distilled water and slowly drop the reaction solution into a saturated solution.
- Ammonium hexachloroosmate (129 mg, 0.293 mmol) and starting material (15) (120 mg, 0.293 mmol) are put in a glass culture tube, and ethylene glycol (3 mL) is added to make a mixed solution. After that, argon gas was blown in for 10 minutes to create an argon atmosphere in the glass culture tube, and then refluxed at 140 o C for 6 hours. Add an excess of ammonium hexafluorophosphate to distilled water and slowly drop the reaction solution into a saturated solution. A precipitate formed in the solution was filtered and washed with distilled water and an excess of diethyl ether to obtain a brown solid product 23 having a counter ion of PF 6 - .
- Example 3 Analysis of the electrochemical properties of the TPMA-based osmium complex according to the present invention
- Cyclic voltammetry was used to analyze the electrochemical properties of the synthesized TPMA-based osmium complexes.
- a well-washed carbon glass electrode with a diameter of 3 mm was used as a working electrode, and an Ag/AgCl electrode was used as a reference electrode and a Pt electrode was used as a counter electrode for measurement at a scanning rate of 10 mV/s.
- PF 6 - The complex in the form of a counterion was measured at a concentration of 3 mg/mL in an acetonitrile solution of 0.1M TBAP.
- Oxidation/reduction potentials were compared with complexes Nos. 19 to 23 , each having a similar coordination structure to complex No. 18 and containing different substituents.
- Complexes containing electron withdrawing groups (EWG) such as complex No. 19 containing two ethyl ester (-COOEt) groups, complex No. 20 containing one group, and complex No. 22 containing amide (-COONH) groups
- EWG electron withdrawing groups
- complex No. 19 complex No. 19 containing two ethyl ester (-COOEt) groups
- complex No. 20 containing one group
- complex No. 22 containing amide (-COONH) groups The oxidation/reduction potential of complex No. 18 appeared at a more positive value.
- complexes containing an electron donating group (EDG) such as number 21 containing a methyl (-CH 2 -) group and number 23 containing two methoxy (-OMe) groups, are more complex than complex number 18 .
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Electrochemistry (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Pyridine Compounds (AREA)
- Hybrid Cells (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (16)
- 전자전달매개체로서 유용한, 하기 화학식 1 또는 2로 나타내어지는 테트라덴테이트 질소 공여체 리간드를 포함하는 전이금속 착체:[화학식 1][화학식 2]상기 화학식 1 또는 화학식 2에서,M은 Fe, Co, Ru, Os, Rh 및 Ir로 이루어지는 군으로부터 선택되는 하나이고;Ca, Cb, Cc는 질소원자를 하나 이상 포함한 헤테로 고리 화합물로, 바람직하게는 상기 고리 화합물의 2번 위치에서 아민기와 메틸렌기로과 연결되어 있고;Lm1 및 Lm2는 각각 독립적으로 배위된 모노덴테이트 리간드이며;Lb는 질소 또는 산소를 포함하는 바이덴테이트 리간드이고;m은 -1 ~ -5 또는 1 ~ 5 를 나타내는 음전하 혹은 양전하이고;R1, R2 및 R3은 각각 독립적으로 고분자에 연결할 수 있는 반응기가 도입된 링커로 구성된 구조이고;X는 반대이온 (counter ion)이며;n은 반대이온의 수를 의미하며, 1 ~ 5이다.
- 제1항 또는 제2항에 있어서,상기 화학식 1 내지 3의 R1, R2 및 R3은 각각 독립적으로 -H; -F; -Cl; -Br; -I; -NO2; -CN; -CO2H; -SO3H; -NHNH2; -SH; -OH; -NH2; -CH2OH; -CONHCH2CH2NH2; 또는 치환되거나 치환되어 있지 않은 알콕시카보닐, 알킬아미노카보닐, 다이알킬아미노카보닐, 알콕시, 알킬아미노, 다이알킬아미노, 알카닐아미노, 아릴카복시아미도, 하이드라지노, 알킬하이드라지노, 하이드록시아미노, 알콕시아미노, 알킬싸이오, 알케닐, 아릴 또는 알킬인 것인, 전이금속 착체.
- 제1항에 있어서,상기 Lm1 및 Lm2는 각각 독립적으로 -H, -F, -Cl, -Br, -I, -NO2, -NCCH3, -CO, -OH2, -NH3 또는 질소원자를 하나 이상 포함한 헤테로 고리 화합물인 것인, 전이금속 착체.
- 제1항에 있어서,상기 Lb- Lb 는 카테콜, 아세틸아세톤, 2-피콜린산, 2-피리딘카복사마이드, 2,2-바이피리딘 또는 2,2-바이싸이아졸인 것인, 전이금속 착체.
- 제5항에 있어서,상기 헤테로 고리 화합물은 이미다졸, 피리딘, 피리미딘, 피라졸, 아이소옥사졸, 옥사졸, 싸이아졸, 벤조싸이아졸, 벤즈이미다졸, 벤조옥사졸 및 디아자플루오레논으로 이루어지는 군으로부터 선택되는 1종 이상인 것인, 전이금속 착체.
- a) 화학식 3으로 나타내어지는 테트라덴테이트 트리스-피리딘메틸아민계 리간드를 화학식 5의 할로겐화 오스뮴의 암모늄염에 도입하여 화학식 6의 오스뮴 착체를 합성하는 단계; 및b) 화학식 6의 오스뮴 착체에 N-N 리간드, N-리간드, N-O 리간드 및 O-O 리간드로 이루어지는 군으로부터 선택되는 1종 또는 2종의 모노덴테이트리간드 또는 바이덴테이트리간드를 도입하는 단계,를 포함하는 제1항에 따른 화학식 1 또는 2의 전이금속 착체의 제조방법:[화학식 3][화학식 5][(NH4)2OsCl6][화학식 6]상기 식에서 Ca, Cb 및 Cc는 각각 독립적으로 질소원자를 하나 이상 포함한 헤테로 고리 화합물이고;R1, R2 및 R3은 각각 독립적으로 고분자에 연결할 수 있는 반응기가 도입된 링커이다.
- 제10항에 있어서,상기 N 리간드는 -NO2, -NCCH3, -NH3 또는 질소원자를 하나이상 포함한 헤테로 고리 화합물이고,상기 N-N 리간드는 2-피리딘카복사마이드, 2,2’-바이피리딘 또는 2,2’-바이싸이아졸이고,상기 N-O 리간드는 2-피콜린산이고,상기 O-O 리간드는 카테콜 또는 아세틸아세톤인 것인, 방법.
- 제1항 내지 제8항 중 어느 한 항에 따른 전이금속 착체를 전자전달매개체로서 포함하는 장치.
- 제12항에 있어서, 상기 장치는 전기화학적 바이오센서인 것인, 장치.
- 제12항에 있어서, 상기 장치는 삽입가능한 것인 장치.
- 액체성 생체시료를 산화환원시킬 수 있는 효소; 및제1항 내지 제8항 중 어느 한 항의 전이금속 착체를 전자전달매개체로 포함하는 전기화학적 바이오센서용 센싱 막.
- 제15항에 있어서, 상기 효소는탈수소효소 (dehydrogenase), 산화효소 (oxidase), 및 에스테르화효소 (esterase)로 이루어진 군에서 선택된 1종 이상의 산화환원효소; 또는탈수소효소, 산화효소, 및 에스테르화효소로 이루어진 군에서 선택된 1종 이상의 산화환원효소와 플라빈 아데닌 디뉴클레오타티드 (flavin adenine dinucleotide, FAD), 니코틴아미드 아데닌 디뉴클레오티드 (nicotinamide adenine dinucleotide, NAD), 및 피롤로퀴놀린 퀴논 (Pyrroloquinoline quinone, PQQ)로 이루어진 군에서 선택된 1종 이상의 보조인자를 포함하는 것인, 전기화학적 바이오센서용 센싱 막.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023540608A JP2024505810A (ja) | 2020-12-31 | 2021-12-28 | テトラデンテート窒素供与体リガンドを含む遷移金属錯体およびこれを含む電気化学的バイオセンサー |
CN202180094860.4A CN117015547A (zh) | 2020-12-31 | 2021-12-28 | 含有四齿氮供体配体的过渡金属复合物和包括该复合物的电化学生物传感器 |
US18/269,062 US20240158426A1 (en) | 2020-12-31 | 2021-12-28 | Transition metal complex containing tetradentate nitrogen donor ligand and electrochemical biosensor comprising same |
AU2021415745A AU2021415745A1 (en) | 2020-12-31 | 2021-12-28 | Transition metal complex containing tetradentate nitrogen donor ligand and electrochemical biosensor comprising same |
EP21915780.7A EP4273152A4 (en) | 2020-12-31 | 2021-12-28 | TRANSITION METAL COMPLEX CONTAINING TETRADENTATE NITROGEN DONOR LIGAND AND ELECTROCHEMICAL BIOSENSOR COMPRISING SAME |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200189139A KR20220096569A (ko) | 2020-12-31 | 2020-12-31 | 테트라덴테이트 질소 공여체 리간드를 포함하는 전이금속 착체 및 이를 포함하는 전기화학적 바이오센서 |
KR10-2020-0189139 | 2020-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022145982A1 true WO2022145982A1 (ko) | 2022-07-07 |
Family
ID=82260701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/020070 WO2022145982A1 (ko) | 2020-12-31 | 2021-12-28 | 테트라덴테이트 질소 공여체 리간드를 포함하는 전이금속 착체 및 이를 포함하는 전기화학적 바이오센서 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20240158426A1 (ko) |
EP (1) | EP4273152A4 (ko) |
JP (1) | JP2024505810A (ko) |
KR (1) | KR20220096569A (ko) |
CN (1) | CN117015547A (ko) |
AU (1) | AU2021415745A1 (ko) |
WO (1) | WO2022145982A1 (ko) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080197026A1 (en) * | 2001-05-11 | 2008-08-21 | Fei Mao | Transition metal complexes with (pyridyl)imidazole ligands |
WO2013126745A2 (en) * | 2012-02-23 | 2013-08-29 | Carnegie Mellon University | Ligands designed to provide highly active catalyst complexes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220096570A (ko) * | 2020-12-31 | 2022-07-07 | 주식회사 아이센스 | 펜타플루오로페닐 에스터를 포함하는 고분자 및 이를 포함하는 전기화학적 바이오센서 |
-
2020
- 2020-12-31 KR KR1020200189139A patent/KR20220096569A/ko not_active Application Discontinuation
-
2021
- 2021-12-28 US US18/269,062 patent/US20240158426A1/en active Pending
- 2021-12-28 JP JP2023540608A patent/JP2024505810A/ja active Pending
- 2021-12-28 WO PCT/KR2021/020070 patent/WO2022145982A1/ko active Application Filing
- 2021-12-28 EP EP21915780.7A patent/EP4273152A4/en active Pending
- 2021-12-28 CN CN202180094860.4A patent/CN117015547A/zh active Pending
- 2021-12-28 AU AU2021415745A patent/AU2021415745A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080197026A1 (en) * | 2001-05-11 | 2008-08-21 | Fei Mao | Transition metal complexes with (pyridyl)imidazole ligands |
WO2013126745A2 (en) * | 2012-02-23 | 2013-08-29 | Carnegie Mellon University | Ligands designed to provide highly active catalyst complexes |
Non-Patent Citations (5)
Title |
---|
KOJIMA, T.FUKUZUMI, S., CHEM. EUR. J., vol. 13, 2007, pages 8212 - 8222 |
LI AO, WHITE JESSICA K., ARORA KARAN, HERROON MACKENZIE K., MARTIN PHILIP D., SCHLEGEL H. BERNHARD, PODGORSKI IZABELA, TURRO CLAUD: "Selective Release of Aromatic Heterocycles from Ruthenium Tris(2-pyridylmethyl)amine with Visible Light", INORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON , US, vol. 55, no. 1, 4 January 2016 (2016-01-04), Easton , US , pages 10 - 12, XP055947422, ISSN: 0020-1669, DOI: 10.1021/acs.inorgchem.5b02600 * |
O'NEILL E. S., KOLANOWSKI J. L., YIN G. H., BROADHOUSE K. M., GRIEVE S. M., RENFREW A. K., BONNITCHA P. D., NEW E. J.: "Reversible magnetogenic cobalt complexes", RSC ADVANCES, vol. 6, no. 36, 1 January 2016 (2016-01-01), pages 30021 - 30027, XP055947424, DOI: 10.1039/C6RA04643F * |
RENFREW ANNA K., BRYCE NICOLE S., HAMBLEY TREVOR W.: "Delivery and release of curcumin by a hypoxia-activated cobalt chaperone: a XANES and FLIM study", CHEMICAL SCIENCE, ROYAL SOCIETY OF CHEMISTRY, UNITED KINGDOM, vol. 4, no. 9, 1 January 2013 (2013-01-01), United Kingdom , pages 3731, XP055947423, ISSN: 2041-6520, DOI: 10.1039/c3sc51530c * |
See also references of EP4273152A4 |
Also Published As
Publication number | Publication date |
---|---|
CN117015547A (zh) | 2023-11-07 |
EP4273152A1 (en) | 2023-11-08 |
US20240158426A1 (en) | 2024-05-16 |
JP2024505810A (ja) | 2024-02-08 |
EP4273152A4 (en) | 2024-06-12 |
KR20220096569A (ko) | 2022-07-07 |
AU2021415745A1 (en) | 2023-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021125791A1 (ko) | C-n 리간드를 갖는 신규 전이금속 전자전달 착체 및 이를 이용한 전기화학적 바이오센서 | |
WO2021096284A1 (ko) | Glp-1 수용체 작용제 및 이의 용도 | |
WO2010093191A2 (en) | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | |
WO2012102544A2 (ko) | 신규한 유기염료 및 이의 제조방법 | |
WO2010147425A2 (ko) | 신규한 유기염료 및 이의 제조방법 | |
WO2009145456A2 (ko) | 헤테로사이클 유도체 | |
WO2022216094A1 (ko) | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 | |
WO2022225313A1 (ko) | 전이금속 착물 또는 산화-환원 중합체를 포함하는 전기화학적 바이오센서 또는 전기화학적 바이오센서용 센싱 막 | |
WO2022145982A1 (ko) | 테트라덴테이트 질소 공여체 리간드를 포함하는 전이금속 착체 및 이를 포함하는 전기화학적 바이오센서 | |
WO2020149553A1 (ko) | 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 | |
CN114276354A (zh) | 1-氨基苯并[4,5]咪唑并[1,2-a]吡嗪-3-甲酰胺类化合物及其制备和应用 | |
WO2020060194A1 (ko) | 폴리알릴글라이시딜에터 기반의 산화-환원 고분자 및 이를 이용한 전기화학적 바이오센서 | |
AU2021226297B2 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
WO2013105753A1 (en) | Substituted piperidine derivatives and methods for preparing the same | |
WO2021086069A1 (ko) | Ezh2 저해제 및 e3 리가제 바인더를 포함하는 화합물 및 이를 유효성분으로 함유하는 ezh2 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2020022787A1 (ko) | Jnk 저해 활성을 갖는 신규한 이미다졸 유도체 및 이를 포함하는 약학적 조성물 | |
WO2022146115A1 (ko) | 펜타플루오로페닐 에스터를 포함하는 고분자 및 이를 포함하는 전기화학적 바이오센서 | |
WO2011049274A1 (en) | Imidazole derivatives and compositions for treating melanoma | |
WO2021133144A1 (ko) | 신규한 유기 전자전달매개체 및 이를 포함하는 장치 | |
CA1303038C (en) | Diselenobis benzoic acid amides of primary heterocyclic amines, process for producing the same and pharmaceutical compounds comprisingthe same | |
WO2022108377A1 (ko) | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 | |
WO2010032986A2 (ko) | 신규 5-(4-아미노페닐)-이소퀴놀린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 raf 키나제의 과활성에 의해 유발되는 질환의 예방 또는 치료용 조성물 | |
WO2022270881A1 (ko) | 단백질 키나아제 억제제로서의 신규한 화합물 | |
WO2012157900A2 (ko) | 18f-표지 pet 방사성의약품의 전구체 및 그 제조방법 | |
WO2016163727A2 (ko) | 황화수소 검출용 방사성 프로브 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21915780 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18269062 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023540608 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2021415745 Country of ref document: AU Date of ref document: 20211228 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021915780 Country of ref document: EP Effective date: 20230731 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180094860.4 Country of ref document: CN |